Literature DB >> 1559294

Hormone replacement therapy: risks and benefits.

S I Whitcroft1, J C Stevenson.   

Abstract

Mesh：

Year:  1992        PMID： 1559294     DOI： 10.1111/j.1365-2265.1992.tb02896.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  8 in total

Review 1.  Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.

Authors:  B Andersson
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

2.  An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells.

Authors:  Xiaohua Gao; Linda Yu; Lysandra Castro; Alicia B Moore; Tonia Hermon; Carl Bortner; Maria Sifre; Darlene Dixon
Journal:  Toxicol Lett       Date:  2010-03-15       Impact factor: 4.372

Review 3.  Hormone replacement therapy. Risks, benefits, and costs.

Authors:  M D Delva
Journal:  Can Fam Physician       Date:  1993-10       Impact factor: 3.275

Review 4.  Familial breast cancer.

Authors:  D G Evans; I S Fentiman; K McPherson; D Asbury; B A Ponder; A Howell
Journal:  BMJ       Date:  1994-01-15

5.  Effects of ipriflavone administration on bone mass and metabolism in ovariectomized women.

Authors:  M Gambacciani; A Spinetti; B Cappagli; F Taponeco; R Felipetto; D Parrini; N Cappelli; P Fioretti
Journal:  J Endocrinol Invest       Date:  1993-05       Impact factor: 4.256

Review 6.  Estrogen replacement therapy in women at increased risk for breast cancer.

Authors:  R Vassilopoulou-Sellin
Journal:  Breast Cancer Res Treat       Date:  1993-11       Impact factor: 4.872

7.  The effect of different hormone replacement therapy regimens on the mechanical properties of rat vertebrae.

Authors:  D Chachra; M Kasra; C M Vanin; N J MacLusky; R F Casper; M D Grynpas
Journal:  Calcif Tissue Int       Date:  1995-02       Impact factor: 4.333

8.  Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.

Authors:  F Hawkins; D Rigopoulou; K Papapietro; M B Lopez
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.